Lung Cancer | Specialty

Dr. Jotte on the IMpower131 Findings in Squamous NSCLC

June 4th 2018

Robert M. Jotte, MD, PhD, medical director and co-chair, USON Thoracic Committee, Rocky Mountain Cancer Centers, discusses the phase III findings of the IMpower131 trial, which looked at the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) in patients with advanced squamous non

Pegilodecakin Plus PD-1 Inhibitor Shows Potential in NSCLC

June 4th 2018

Combining pegilodecakin with nivolumab or pembrolizumab induced an overall response rate of 41% in patients with advanced non–small cell lung cancer.

Pembrolizumab Plus Chemo Emerges as New Standard in Frontline Squamous NSCLC

June 3rd 2018

Adding pembrolizumab to frontline carboplatin/paclitaxel or nab-paclitaxel reduced the risk of death by 36% compared with chemotherapy alone in patients with metastatic squamous non–small cell lung cancer.

Frontline Pembrolizumab Bests Chemo in NSCLC, Especially in PD-L1-High Subgroup

June 3rd 2018

Patients with non-small cell lung cancer treated with frontline pembrolizuma lived 4 to 8 months longer than those who received standard of care chemotherapy.

Dr. Oxnard Discusses the Circulating Cell-Free Genome Atlas Study

June 3rd 2018

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the design and importance of the Circulating Cancer Genome Atlas (CCGA) study in an interview with OncLive during the 2018 ASCO Annual Meeting.

Matched Targeted Therapy Extends Survival in Advanced Hard-to-Treat Cancers

June 2nd 2018

Personalized therapy based on tumor molecular profiling resulted in improved overall survival for patients with advanced, hard-to-treat cancers.

cfDNA Assays Demonstrate High Specificity for Early Stage Lung Cancer Detection

June 2nd 2018

Initial results from the Circulating Cell-Free Genome Atlas study strongly suggest that cell-free DNA tests can be used with a high degree of specificity to detect signs of early stage lung cancer.

Atezolizumab Plus Chemo Extends PFS in Frontline Squamous NSCLC

June 2nd 2018

The addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) delayed the risk of progression or death by 29% compared with chemotherapy alone for patients with advanced squamous NSCLC.

LOXO-292 Shows Impressive Response Rates for RET-Positive Tumors

June 2nd 2018

The highly-selective RET inhibitor LOXO-292 demonstrated robust clinical activity across RET-altered solid tumors, including in patients with brain metastases and the RET V804M gatekeeper mutation.

Practice Changes for Use of Immunotherapy in NSCLC: Q&A

June 2nd 2018

Using Immunotherapy Beyond Progression in NSCLC

June 2nd 2018

Optimizing Immunotherapy in the NSCLC Treatment Paradigm

June 2nd 2018

Tumor Mutational Burden in NSCLC: Should it be Routine?

June 2nd 2018

Impact of Data on the Real-Life Treatment of NSCLC

June 2nd 2018

Important Data in the Squamous NSCLC Population

June 2nd 2018

IMPower150: Implications for the Treatment of NSCLC

June 2nd 2018

CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC

June 2nd 2018

Actual Use of Pembrolizumab and Chemotherapy in NSCLC

June 2nd 2018

KEYNOTE Trial Data: Pembrolizumab's Role in NSCLC

June 2nd 2018

ASCO 2018: Dr. Westin Sheds Light on PARP Inhibitor Abstracts in Ovarian Cancer

June 2nd 2018